

Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Potential applications of metagenomics to assess the biological effects of food**
2 **structure and function**

3 Tasha M. Santiago-Rodriguez^{1,2}, Raul Cano^{1,2} and Rafael Jiménez-Flores^{1,3,*}

4 ¹Center of Applications in Biotechnology, California Polytechnic State University, San Luis
5 Obispo, CA 93407; ²Department of Biological Sciences, California Polytechnic State University,
6 San Luis Obispo, CA 93407; ³Food Science and Technology, Ohio State University, Columbus,
7 Ohio, 43210

8
9 **ABSTRACT**

10 Metagenomics, or the collective study of genomes is an important emerging area in microbiology
11 and related fields, and is increasingly being recognized as a tool to characterize the microbial
12 community structure and function of diverse sample types. Metagenomics compares sequences
13 to existing databases to enable the identification of potential microbial reservoirs and predict
14 specific functions; yet, metagenomics has not been widely applied to understand how changes in
15 food structure and composition affect microbial communities and their function in the human
16 gut. Studies are needed to understand the digestion of food products, and to measure their
17 effectiveness in preserving a healthy microbiome, as well as intestinal function. We suggest the
18 use of metagenomics with validation techniques such as Polymerase Chain Reaction (PCR),
19 cloning and functional assays to assess the biological effects of food structure and function.

20
21 **Keywords:** Food structure, Metagenomics, Microbiome, Milk Fat Globule

22 ***Corresponding author:** Rafael Jimenez-Flores, jimenez-flores.1@osu.edu

23

24 INTRODUCTION

25 Structure and functionality measurements have revolutionized the field of food science
26 mainly because both food flavor and the potential beneficial health effects are among the
27 consumers' interests today; yet, we are just beginning to elucidate this association. This is
28 particularly the case for milk products, which have been extensively consumed for centuries, but
29 formulations have been refined throughout the years to meet these criteria. The development of
30 models capable to differentiate the digestion and potential health benefits of the different
31 structures that can be created with modern food technology offer a fertile ground for research,
32 and will continue to provide a forum for novel ideas in modern food processing, and a more
33 efficient method to measure the efficiency and benefit of one structure over another. We propose
34 that the emerging field of metagenomics, with all its variations, is of importance to understand
35 the biological changes induced by modifications in food structure. In the present review, we have
36 turned to the field of metagenomics with the potential of measuring the effect that the structure
37 of different milk product components has on the function of the intestinal microbiota.

38

39 WHAT IS METAGENOMICS?

40 Metagenomics, or the collective study of genomes is an important emerging area in
41 microbiology and related fields, and is increasingly being recognized as a tool to characterize the
42 microbial community structure and function of diverse sample types^{1,2}. One of the most
43 important characteristics of metagenomics is the ability to characterize microbial communities

44 that are not able to grow under specific conditions or in pure cultures³. It is estimated that the
45 great majority of microorganisms in diverse sample types are uncultivable, making
46 metagenomics of great potential in fields such as food science, where the majority of the
47 microbial assays still depend on those microorganisms that can be grown. In the following
48 section, we discuss the most important approaches to study microbial communities, namely
49 targeted amplicon sequencing (TAS) and shotgun metagenomics as a way to direct readers into
50 the potential applications of these techniques in the field of food science.

51

52 **Sequencing approaches**

53 ***Targeted amplicon sequencing (TAS)***

54 A large number of studies have characterized the microbial composition of diverse
55 samples using TAS. TAS relies on the amplification of phylogenetic markers, which usually
56 include the 16S (bacterial) or 18S rRNA (microbial eukaryotic) genes⁴. Variable regions from
57 these phylogenetic markers, including the V3, V4, V5 or V6 of the 16S rRNA gene (which
58 usually enables a reliable distinction of bacteria up to the genus level)⁴, or the ITS region of the
59 18S rRNA gene are usually targeted⁵. Data are usually analyzed using tools such as Qiime or
60 Mothur in order to infer phylogenetic relationships with existing reference databases such as
61 Greengenes or Silva^{6,7}. The relative abundance of Operational Taxonomical Units (OTUs) is
62 then used to determine taxonomy, and microbial community diversity⁸. While TAS has shown
63 to be relatively cost-effective, some *a-priori* knowledge of the microbial composition of a
64 sample is expected⁹, and species-level resolution is often not reached¹⁰, making techniques such
65 as Polymerase Chain Reaction (PCR) and its variants of great utility to characterize specific

66 microbial communities with greater resolution. TAS data are now increasingly being coupled
67 with shotgun metagenomics data (described below) to obtain a greater resolution of the
68 biological structure and function of a sample. In the dairy industry, for example, TAS has been
69 used to determine the bacterial composition of raw milk, ripened curd and mozzarella cheese.
70 Raw milk has shown to have the greatest number of species compared to ripened curd and
71 mozzarella cheese, possibly more than those that can be cultured ¹¹.

72

73 *Shotgun metagenomics*

74 Unlike TAS, shotgun metagenomics is a non-targeted approach that provides the
75 advantage of characterizing microbial communities (bacteria, microbial eukaryotes and archaea),
76 and viruses (prokaryotic and eukaryotic) together ¹². While results provide insights into the
77 taxonomy of the microorganisms in a sample, they also provide information about the enzymes
78 and pathways that may be associated with carbohydrate, lipid and amino acid metabolism.
79 Taxonomic composition of microbial communities from shotgun metagenomic data can be
80 determined using tools such as the metagenomics analysis server (MG-RAST) and the Classifier
81 for metagenomics sequences (ClAMS) ^{13,14}. Taxonomic classification of shotgun metagenomic
82 data relies on sequence annotation based on existing databases, which need to be updated and
83 curated regularly so that sequence annotation is reliable.

84

85 Shotgun metagenomics data provide an advantage over TAS in that functional prediction
86 analyses can be performed using tools such as the metagenomics server MG-RAST, Kyoto
87 Encyclopedia of Genes and Genomes (KEGG) ¹⁵, Carbohydrate Active Enzymes (CAZy)

88 database^{16, 17}, and/or the Interactive Pathway Explorer (iPATH)¹⁸. These functional prediction
89 analyses also rely on existing databases and how these have been annotated and curated.
90 Function prediction based on shotgun metagenomics data represents one of the first steps to
91 assign functions to specific microbial communities and identify potential reservoirs. Functional
92 prediction from shotgun metagenomics data has provided insights into potential metabolic
93 signatures and biomarkers of human diseases including Crohn's disease and type 1 diabetes,
94 among many other health conditions, proving to be a reliable approach to predict the function of
95 specific microbial reservoirs in diverse sample types.

96

97 **METAGENOMICS AND FOOD STRUCTURE**

98 While TAS has been widely applied to understand the taxonomic composition of diverse
99 samples, the next essential step in both microbiome research and the field of food structure and
100 function is to identify enzymes, pathways and potential mechanisms associated with specific
101 microbial communities. Shotgun metagenomics has the advantage over TAS in that both the
102 taxonomy and function can be determined and predicted. Identifying the enzymes, pathways and
103 mechanisms and how these operate under different conditions may perhaps be of greater value in
104 the field of food structure and function than determining the taxonomy of specific samples alone.
105 Predicted function(s) elicited by diverse food structures would have to be accompanied by the
106 validation of metagenomics data using PCR, expression of genes of interest and function assays.
107 We will use in great part the structure of the milk fat globule membrane (MFGM) as an example
108 on how metagenomics can be used in studies related to food structure. MFGM are an essential
109 component of maternal milk, and possess important functional and nutritional characteristics that
110 are known to have beneficial health effects^{19, 20}.

111

112 Some of our findings using confocal microscopy, atomic force microscopy and
113 proteomics have provided insights of the organization of the MFGM. Results have also shown
114 that MFGM are a source of bioactive molecules including glycerophospholipids, gangliosides,
115 cerebroside, cholesterol and glycoproteins ²¹. We have also been interested in the relationship of
116 the MFGM structure to specific microbe interactions. We determined the effects of processing of
117 the milk product on both the structure and composition of the MFGM by measuring the binding
118 interactions between lactic acid bacteria and the MFGM. Table 1 shows how, by using optical
119 tweezers, we were able to measure the difference in binding force and interactions between
120 similar types of lactic acid bacteria and the surface of the bovine MFGM. We also devised a
121 means to measure the amount of interaction between these bacteria and milk buttermilk powder
122 (high in MFGM content) using a gradient centrifugation method. In this procedure, we measured
123 the DNA recovered at the bottom of the centrifuge tubes as a result of the different binding
124 characteristics. Cells that bound tightly to the fat globules remained at the surface along with the
125 fat in the centrifuge tube (Figure 1A). In contrast, bacteria that did not interact with the fat
126 globules were recovered at the bottom of the tubes (Figure 1B). These data are mainly the
127 phenotypic effects of bacteria/MFGM interactions; therefore, a large missing part in this research
128 area is the potential changes in gene expression resulting from bacteria/MFGM interactions.
129 Global changes in gene expression are increasingly being explored using RNA-sequencing, or
130 RNA-seq, a variation of shotgun metagenomics, where complementary DNA (cDNA) libraries
131 are constructed from messenger RNA (mRNA). The identity of the genes and the level of
132 expression can then be explored using RNA-seq. Another key question that has not been
133 investigated in great detail is the potential physiological function(s) of MFGM to the infant gut

134 microbiome. TAS results have shown that breast- vs bottle-feeding can significantly alter the
135 structure and succession of the infant gut microbiome^{22,23}. More recent studies have identified
136 the specific structures of maternal milk that are associated with maintaining infant health during
137 development. For instance, leptin and certain fatty acids present in the milk of obese mothers
138 have been associated with children also developing obesity²⁴; yet, how MFGM may be
139 associated with the gut microbiome, maintaining health and preventing diseases such as obesity
140 remain to be addressed. Also, efforts to mimic MFGM present in maternal breast milk have
141 shown promising results, opening a new are in infant gut microbiome research²⁵.

142

143 Shotgun metagenomics is also increasingly being applied to identify the association of
144 microbial communities with molecules and enzymes in specific carbohydrate, lipid and amino
145 acid pathways. In the following section we discuss some of these findings.

146

147 **Carbohydrates**

148 Carbohydrates are classified as mono-, di-, oligo- and poly-saccharides, and some types
149 are resistant to human hydrolytic enzymes. Non-digested carbohydrates provide a major energy
150 source for the growth of certain microorganisms in the gut^{26,27}. The different assemblages of
151 monosaccharides into higher structures results in a great diversity of carbohydrates. Complex
152 carbohydrates in the form of fruits, vegetables and cereals constitute a good proportion of human
153 diets²⁸, and their consumption is known to affect the composition and function of the gut
154 microbiome. For instance, weight-loss diet studies, where total carbohydrate intake is decreased,
155 have shown that there is a reduction in the detection of microbially-produced short-chain fatty

156 acids (SCFA), which include acetate, propionate and butyrate, known to be beneficial for gut
157 health in fecal samples²⁹. In addition, there is a significant decrease in the proportion of
158 Bifidobacteria and butyrate-producing *Lachnospiraceae*, and an increase in *Ruminococcus*
159 *bromii*. Subjects with the smallest ruminococcal populations have shown to fail to fully ferment
160 dietary resistant starch, suggesting that this bacterial group might play a key role in this process
161³⁰. To the best of our knowledge, most metagenomics studies in the area of carbohydrate
162 digestion focus on the effect of complex carbohydrates to the gut microbiome structure, opening
163 the opportunity to decipher the metabolic profiles that could potentially result from the
164 consumption of diverse forms of carbohydrates. It is also known that carbohydrate utilization and
165 central metabolism functions seem to be more dedicated to the degradation of complex
166 carbohydrates rather than simple sugars³¹. Metagenomic studies focusing on how simple
167 carbohydrates affect both the human gut microbiome structure and function are still needed. This
168 could be performed with human milk, for example, which is known to harbor a great variety of
169 monosaccharides including D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc),
170 L-fucose (Fuc), and N-acetylneuraminic acid (NeuAc)³². Testing the potential effect(s) of these
171 monosaccharides using *in-vivo* and *in-vitro* models could provide insights into the metabolic
172 response of specific microbial components that could potentially influence human gut
173 microbiome function.

174

175 Complex carbohydrates are degraded by enzymes known as carbohydrate active enzymes
176 (CAZymes) that can be human- or microbially-encoded³³. Shotgun metagenomic analyses have
177 shown to be useful in the identification of CAZymes, where the majority are microbially-
178 encoded and are present in diverse human surfaces including the nares, oral cavity, skin and

179 stool, with the latter showing the highest relative abundance²⁶. The majority of the CAZymes in
180 the human gut aid in the degradation of plant cell wall and animal glycans, while the remaining
181 aid in the degradation of starch, glycogen, and peptidoglycans³⁴. CAZymes belonging to the
182 glycoside hydrolases (GHs) can break the glycosidic bond between carbohydrates or between a
183 carbohydrate and a non-carbohydrate moiety³⁵. Another type of CAZyme that breaks bonds with
184 the insertion of a water molecule are the polysaccharide lyases (PLs)³⁵. GH families are more
185 abundant than PL families, with 130 and 22 families discovered so far, respectively; thus, we
186 will further focus on GHs.

187

188 Several human-encoded GHs including GH1, GH9, GH13, GH18, GH31, GH35 and
189 GH37 are known to be involved in carbohydrate degradation; yet, microorganisms play the
190 major role in carbohydrate degradation using GHs that differ from those that are human-encoded
191³⁶. The availability of databases such as the Carbohydrate-Active enzyme (<http://www.cazy.org/>)
192 makes it possible to identify GH sequence homology in a sample and identify the potential
193 reservoirs. At the phylum level, it is known that the Firmicutes and Bacteroidetes represent the
194 most abundant reservoirs of GHs, opening the opportunity to understand their role in
195 carbohydrate metabolism³⁶. In the field of dairy science and nutrition, oligosaccharides present
196 in milk and their digestion by bacteria and other microorganisms in the gut is an increasing
197 expanding area of research; however, metagenomics may perhaps represent the most
198 comprehensive initial approach to understand the potential effect(s) of oligosaccharides to the
199 gut microbiome, and to identify the enzymes and reservoirs involved.

200

201 Lipids

202 Lipids include fats, sterols, mono-, di- and tri-glycerides, and phospholipids, and act as
203 energy reservoirs, for signaling processes and structural components³⁷⁻³⁹. Lipids are highly
204 diverse, essential food components, and their homeostasis is essential to maintain health; yet,
205 they are also associated with health-related conditions including obesity. Obesity has been
206 strongly linked to changes in the structure of the gut microbiome. For instance, a high-fat diet is
207 known to affect the relative abundance of the major gut bacteria phyla. Individuals under a low-
208 fat diet have shown to possess a lower relative abundance of Bacteroidetes and a higher relative
209 abundance of Firmicutes. Individuals under a high-fat diet have demonstrated the opposite effect
210^{40, 41}. Interestingly, lean, germ-free mice have been shown to gain more weight when receiving
211 the gut contents of obese mice than recipients of the gut contents of lean mice, further supporting
212 that the microbial components of stool have an effect on energy utilization⁴². The predicted
213 increased capacity for dietary energy harvest by the obese mice microbiome was validated using
214 biochemical assays. Future studies are needed to understand the specific microbial components
215 at the species level of the human microbiome that may be directly or indirectly involved in
216 conditions such as obesity. Identifying these components could potentially be used in the future
217 as a tool to counteract the increased energy harvest capacity from specific microorganisms that
218 may lead to conditions such as obesity.

219

220 The structure in which the lipids are presented to the gut is also of great relevance in the
221 field of food science, but it remains unknown how different structures affect the human gut
222 microbiome⁴³. Identifying the specific microbial components associated with energy harvest will
223 aid in the understanding of the microbial taxonomy structure associated with the digestion of

224 milkfat and related products in the human gut. Partial hydrolysis (lipolysis) of milkfat results in
225 specific flavors of dairy products and this, in part, will depend on the degree of lipolysis.
226 Lypolytic enzymes are involved in the degradation of milkfat and include lipases and esterases,
227 and both are utilized to produce desire flavors in dairy products. Metagenomics has been
228 previously utilized to search for novel lypolytic enzymes in unconventional samples such as
229 aquatic environments, and has proven to be a successful tool in the initial screening of novel
230 lypolytic enzymes⁴⁴. It is not well known how the gut microbiota utilizes lypolytic enzymes to
231 digest milkfat, opening the opportunity to utilize microbiome analyses and shotgun
232 metagenomics to identify the specific microbial components, as well as the enzymes and
233 pathways associated with the process. Results will provide further insights into possible changes
234 in the gut microbiome, if any, after the digestion of milkfat and related products and/or if these
235 are responsible for maintaining gut health. In fact, previous studies have shown potential
236 beneficial effects of ingesting milk products in re-shaping the gut microbiota. A previous study
237 demonstrated that consumption of fermented milk products results in changes in the gut
238 microbiota in inflammatory bowel syndrome (IBS) patients, showing overall beneficial effects;
239 yet, how milk products can potentially modulate the gut microbiota of healthy subjects remains
240 to be investigated⁴⁵.

241

242 Lipids can also affect the metabolic capabilities of the gut microbiome. For instance,
243 lipid-utilizing genes are enriched in obese individuals⁴⁶. Another study found that obese subjects
244 have higher levels of SCFA in their stool, indicating that colonic fermentation differs in lean and
245 obese subjects⁴¹. Studies utilizing mouse models suggested that the ability of the microbiome to
246 influence energy balance is dependent on the capacity of the microbes to suppress expression of

247 angiotensin-like protein 4, or fiaf, a gut-derived inhibitor of human lipoprotein lipase⁴⁷. When
248 germ-free mice received the gut contents of normal mice, fiaf was suppressed, resulting in a
249 greater proportion of triglycerides being stored. While there is some conflicting evidence
250 suggesting that a high-fat diet does not always result in fluctuations of Firmicutes and
251 Bacteroidetes, the gut microbiome does respond to lipids and contribute to host energy balance,
252 probably due to the utilization of several different signaling mechanisms⁴⁶.

253

254 Metagenomic studies can provide a starting point to identify genes associated with lipid
255 metabolism and associated signaling pathways, but these would need to be coupled with other
256 techniques such as lipidomics. Lipidomics is the global study of lipids, including pathways and
257 networks in biological systems, and has been increasingly utilized during the last years due to the
258 advances in mass spectrometry (MS), computational methods and systems biology approaches.
259 In fact, lipidomic studies define the biochemical mechanisms of lipid-related diseases through
260 identifying alterations in cellular lipid metabolism, trafficking, as well as homeostasis.
261 Lipidomics may be an essential tool to understand the role that the gut microbiota plays in the
262 complex lipid-host metabolism in association with health and diverse disease phenotypes. A
263 lipidomics approach, that includes metagenomics, mass spectrometry and systems biology may
264 also be applied to understand the global changes in metabolic pathways in association with the
265 ingestion of milkfat, related products and MFGM⁴⁸.

266

267 MFGM is a conserved structure in the milk that follows a very specific function in milk
268 expression. The structure of MFGM also plays a role in digestion, a hypothesis that has some

269 early support^{43, 49}. A previous study showed that the composition of plasma lipids can be
270 different if milk fat is consumed as free molecules or as native fat globules (i.e. homogenized
271 droplets). The experiment was designed so that milk samples had exactly the same composition,
272 but in different physical states: as free fat, natural cream (which contained the basic natural
273 structure of the MFGM), small natural fat globules in cream, and homogenized cream. Their
274 results showed that the enrichment in plasma triacylglycerides (TAG) in the rats fed the
275 different equi-caloric diets was lower with emulsified milk fat compared with anhydrous milk
276 fat. Moreover, during digestion and absorption, fatty acids (FA) profile of plasma lipids was
277 different for the homogenized cream than for the free fat. These data show that dairy products
278 with the same composition, but varying fat supra-structures result in different kinetics of lipid
279 digestion which could be a health-concern.

280

281 **Amino Acids**

282 Amino acids support the growth and survival of gut bacteria, and regulate energy and
283 protein homeostasis. Gut bacteria break down proteins into peptides and amino acids, indicating
284 that they have an important role in amino acid homeostasis. Amino acids derived from dietary
285 protein sources may serve as substrates for bioconversion by the gut microbiome. *Clostridium*
286 spp., *Bacillus* spp., *Lactobacillus* spp., *Streptococcus* spp., and Proteobacteria are the most
287 abundant groups responsible for amino acid fermentation in the small intestine, while
288 *Clostridium* spp. and Peptostreptococci appear to be the most abundant groups involved in amino
289 acid fermentation in the large intestine. Lysine, arginine, glycine, valine, and isoleucine are
290 among the preferred substrates for gut bacteria, and result in the generation of a complex mixture
291 of metabolic end products including, but not limited to ammonia, branched-chain fatty acids

292 (BCFA), and SCFA. The production of SCFA suggests an interaction between microbial activity
293 and host amino acid, and SCFA homeostasis. Diverse microbial enzymes may contribute to
294 mammalian amino acid metabolism by generating bioactive metabolites in the intestine. One
295 such class of enzymes, amino acid decarboxylases, is widely prevalent in gut microbes. When
296 combined with amino acid transport systems, amino acid decarboxylases link dietary compounds
297 with microbial metabolism and signaling with the gut mucosa^{50, 51}.

298

299 Human milk and related products could represent valuable models to understand the
300 effect of amino acids to the gut microbiome structure and function. Human milk is known to be a
301 source of proteins (8g/L). Approximately 70 % of (human) milk proteins are glycosylated and
302 possess both N-linked and O-linked glycan moieties. The majority of milk glycoproteins are
303 found in skim milk (whey and casein), but the MFGM contains a representative amount of total
304 glycoproteins. The most abundant human milk glycoproteins are α -lactalbumin (17% of total
305 protein), lactoferrin (Lf) (17%), and secretory IgA (sIgA) (11%), belonging to the whey fraction,
306 and κ -casein, from the casein fraction (9%)⁵².

307

308 METAGENOMICS AND FOOD FUNCTION

309 Determining the food structure and the potential biological effects should translate to
310 food function studies. Previous and unpublished studies in our laboratory characterizing the
311 effect of MFGM composition and structure on the binding of lactic acid bacteria indicate that the
312 influence of media on the binding process, and in the expression of proteins in the surface of the
313 bacteria are of great importance in the structure of the bacterial population⁵³. Figure 2 shows the

314 Polyacrylamide gel electrophoresis (PAGE) results of different surface proteins of seven
315 different *Lactobacillus casei* strains when grown in different media. MRS represents the standard
316 laboratory media for lactic acid bacteria, P represents milk permeate obtained after filtering
317 whole milk through a 10,000 MW cut-off ultrafiltration (UF) membrane, M represents the same
318 permeate, but with the MFGM fraction from cream, and ultra-high temperature pasteurization
319 (UHT) represents the whole milk treated with ultra-high temperature for shelf stability. The *L.*
320 *casei* strains included (NCFM, SlpA, SlpB, SlpX, MUB, FpbA and CdpA) are different in their
321 genetic make-up on the S-layer surface proteins⁵⁴. Microscopy results support the differences in
322 protein composition as a result of the exposures of these bacterial strains to different substrates.
323 This is the case for *L. casei* strain SlpA in the presence of cream (Figure 3A), buttermilk (Figure
324 3B) and milk (Figure 3C), where there are significant differences in binding. While
325 understanding the phenotypic effects of lactic acid bacteria in the presence of different substrates
326 is indeed important, it is also necessary to understand the genetic changes associated with the
327 exposure to diverse milk products.

328

329 Application of microbiome analyses and shotgun metagenomics may provide insights
330 into the relative abundance of genes that could potentially be associated with the exposure of
331 diverse substrates (Figure 4). Variations of shotgun metagenomics, including RNA-seq may be
332 used to illustrate global gene expression patterns associated with the phenotypic changes
333 resulting from binding to different substrates. While understanding the relative abundance and
334 global gene expression patterns associated with specific lactic acid bacterial strains is of great
335 importance to the food science field, understanding the global changes in taxonomy, genetic

336 structure and gene pattern expression of the gut microbiome when exposed to variations of milk
337 products would better capture microbial phenotypic changes, including binding properties.

338

339 Another example of bacterial binding in intestines and the effect that surface structures
340 may play in nutrition was presented in a study of the protein-carbohydrate interaction of lactic
341 acid bacteria and mucins found in pig guts⁵⁵. In that study, mucins in the gut interacted with
342 lactic acid bacteria, but the further impact in the microbial community structure and function can
343 only be studied utilizing metagenomics tools. How these phenotypic characteristics, in
344 association with the exposure of diverse milk products affect the function of the gut microbiome
345 would possibly need to be investigated using *in-vitro* and *in-vivo* models. The inclusion of the
346 effects on the human gut microbiome would be of essential value to appreciate the impact of
347 food structure on the biology and function of the digestive system.

348

349 **Food function in association with health and disease**

350 Food function also has a tremendous impact in gut health and disease, possibly because
351 there is a strong association of food function with the gut microbiome. Several of these diseases
352 are metabolic and have been mainly studied using animal models; therefore, results would need
353 to be replicated in humans. In the following section, we discuss recent studies that have explored
354 changes in the gut microbiome function in association with type 2 diabetes and inflammatory
355 bowel disease (IBD).

356

357 Type 2 Diabetes

358 Type 2 diabetes results from an increased production of glucose and resistance to insulin.
359 It is also the combination of diverse factors including genetics, body composition, and nutrition.
360 Insulin resistance is associated with a high fat diet, which modifies the intestinal microbiota,
361 resulting in an increased intestinal permeability and susceptibility to microbial antigens⁵⁶. More
362 recent studies have shown that type 2 diabetes is also associated with an altered gut microbiome
363⁵⁷. Interestingly, when obese individuals were transplanted with the fecal microbiota from lean
364 individuals it resulted in improved insulin sensitivity⁵⁸. Clostridiales bacteria including
365 *Bifidobacterium* and *Faecalibacterium prausnitzii* are known to be in lower abundances in
366 individuals with type 2 diabetes, but it is not clear if it is associated with the development of the
367 disease or if it is a result of it. Butyrate-producing bacteria are decreased in individuals with type
368 2 diabetes, representing a risk for health as butyrate is the preferred source of energy and repair
369 in the human gut.

370

371 Administration of several different prebiotics has shown to have positive effects on the
372 onsets of type 2 diabetes⁵⁹. For instance, an increase in *Bifidobacterium* spp. modulates
373 inflammation in obese mice and is also associated with an increase of glucagon-like peptides and
374 peptide YY, which are known to be beneficial because they decrease insulin-resistance. These
375 data open the opportunity to explore the effects of manipulating the intestinal microbiota in an
376 attempt to revert type 2 diabetes⁶⁰.

377

378 IBD

379 IBD is a condition that includes both Crohn's disease and ulcerative colitis, and affects
380 more than 3 million people worldwide⁶¹. There are several factors that affect the outcome of the
381 condition and include age and diet, although no specific diet has shown to cause or alleviate IBD
382^{61,62}. More recent studies have associated IBD with alterations to the gut microbiome. Evidence
383 suggests that *Enterobacteriaceae* are enriched in individuals suffering the condition, with
384 *Escherichia coli* adherent-invasive strains being identified⁶³. *Fusobacterium varium* has also
385 been associated with the disease, where it can induce colonic mucosal erosion in mice⁶⁴.
386 Specific metabolic pathways have also shown to be different in healthy subjects and those with
387 IBD. The metagenome of individuals with IBD has shown to have a higher representation of
388 pathways associated with oxidative stress, type II secretion systems and bacterial virulence
389 factors^{65,66}.

390

391 IBD relapse can be prevented using antibiotics, but these have shown to decrease the gut
392 bacterial community diversity and possibly promote the proliferation of *E. coli*, which is known
393 to possibly have adverse effects in IBD patients. It has recently been considered to increase gut
394 diversity in subjects with IBD by fecal transplantation as a way to alleviate the condition, which
395 has also shown to be promising in individuals suffering from *Clostridium difficile* infections⁶¹.
396 The use of probiotics has also been evaluated in IBD patients, but these have not shown to have
397 positive in most cases. For instance, a study found that 6 out of the 9 patients went into remission
398 when administered a symbiotic therapy of *Bifidobacterium* and *Lactobacillus*. On the other hand,
399 subjects with ulcerative colitis have shown more promising outcomes. A study found that
400 treatment of ulcerative colitis with a probiotic containing 8 different bacteria including
401 *Bifidobacterium breve*, *B. longum*, *B. infantis*, *Lactobacillus acidophilus*, *L. plantarum*, *L. casei*,

402 *L. bulgaricus*, *S. thermophilus* in parallel with balsalazide, an anti-inflammatory drug had a
403 higher proportion of individuals going into remission⁶⁷. While IBD has shown to be the result of
404 alterations in the gut microbiota and diverse metabolic functions, further study are still needed to
405 elucidate specific pathways, and the development of novel therapies to treat the condition.

406

407 CONCLUSIONS

408 We have described how the emerging field of metagenomics and its variations can be
409 used as tools to further our knowledge of the effects, relevance and significance of changes in
410 food structures. Our contribution has focused on the area of dairy science and how we can
411 measure potential changes in microbial community structure and composition. By applying the
412 “omics” approach, molecular snapshots of biological systems can be generated, allowing the
413 study of comprehensive molecular and metabolic profiles. We envision the field of food structure
414 and function moving from single components towards a systems approach, and how all the
415 components together contribute to a complex network associated with specific biological
416 functions.

417

418 REFERENCES

- 419 1. J. Handelsman, Metagenomics: application of genomics to uncultured microorganisms,
420 *Microbiol Mol Biol Rev*, 2004, **68**, 669-685.
- 421 2. T. Thomas, J. Gilbert and F. Meyer, Metagenomics - a guide from sampling to data
422 analysis, *Microb Inform Exp*, 2012, **2**, 3.

- 423 3. C. S. Riesenfeld, P. D. Schloss and J. Handelsman, Metagenomics: genomic analysis of
424 microbial communities, *Annu Rev Genet*, 2004, **38**, 525-552.
- 425 4. G. Jumpstart Consortium Human Microbiome Project Data Generation Working,
426 Evaluation of 16S rDNA-based community profiling for human microbiome research,
427 *PLoS One*, 2012, **7**, e39315.
- 428 5. J. Brookman, G. Mennim, A. Trinci, M. Theodorou and D. Tuckwell, Identification and
429 characterization of anaerobic gut fungi using molecular methodologies based on
430 ribosomal ITS1 and 18S rRNA, *Microbiology*, 2000, **146**, 393-403.
- 431 6. J. G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F. D. Bushman, E. K. Costello,
432 N. Fierer, A. G. Pena, J. K. Goodrich, J. I. Gordon, G. A. Huttley, S. T. Kelley, D.
433 Knights, J. E. Koenig, R. E. Ley, C. A. Lozupone, D. McDonald, B. D. Muegge, M.
434 Pirrung, J. Reeder, J. R. Sevinsky, P. J. Turnbaugh, W. A. Walters, J. Widmann, T.
435 Yatsunenko, J. Zaneveld and R. Knight, QIIME allows analysis of high-throughput
436 community sequencing data, *Nat Methods*, 2010, **7**, 335-336.
- 437 7. P. D. Schloss, S. L. Westcott, T. Ryabin, J. R. Hall, M. Hartmann, E. B. Hollister, R. A.
438 Lesniewski, B. B. Oakley, D. H. Parks, C. J. Robinson, J. W. Sahl, B. Stres, G. G.
439 Thallinger, D. J. Van Horn and C. F. Weber, Introducing mothur: open-source, platform-
440 independent, community-supported software for describing and comparing microbial
441 communities, *Appl Environ Microbiol*, 2009, **75**, 7537-7541.
- 442 8. J. Kuczynski, J. Stombaugh, W. A. Walters, A. Gonzalez, J. G. Caporaso and R. Knight,
443 Using QIIME to analyze 16S rRNA gene sequences from microbial communities, *Curr*
444 *Protoc Microbiol*, 2012, **Chapter 1**, Unit 1E 5.

- 445 9. J. Kuczynski, C. L. Lauber, W. A. Walters, L. W. Parfrey, J. C. Clemente, D. Gevers and
446 R. Knight, Experimental and analytical tools for studying the human microbiome, *Nat*
447 *Rev Genet*, 2012, **13**, 47-58.
- 448 10. M. Hamady and R. Knight, Microbial community profiling for human microbiome
449 projects: Tools, techniques, and challenges, *Genome Res*, 2009, **19**, 1141-1152.
- 450 11. D. Ercolini, F. De Filippis, A. La Stora and M. Iacono, “Remake” by high-throughput
451 sequencing of the microbiota involved in the production of water buffalo mozzarella
452 cheese, *Applied and environmental microbiology*, 2012, **78**, 8142-8145.
- 453 12. W. L. Wang, S. Y. Xu, Z. G. Ren, L. Tao, J. W. Jiang and S. S. Zheng, Application of
454 metagenomics in the human gut microbiome, *World J Gastroenterol*, 2015, **21**, 803-814.
- 455 13. E. M. Glass, J. Wilkening, A. Wilke, D. Antonopoulos and F. Meyer, Using the
456 metagenomics RAST server (MG-RAST) for analyzing shotgun metagenomes, *Cold*
457 *Spring Harb Protoc*, 2010, **2010**, pdb prot5368.
- 458 14. A. Pati, L. S. Heath, N. C. Kyrpides and N. Ivanova, ClaMS: A Classifier for
459 Metagenomic Sequences, *Stand Genomic Sci*, 2011, **5**, 248-253.
- 460 15. M. Kanehisa, Y. Sato and K. Morishima, BlastKOALA and GhostKOALA: KEGG tools
461 for functional characterization of genome and metagenome sequences, *J Mol Biol*, 2015,
462 DOI: 10.1016/j.jmb.2015.11.006.
- 463 16. V. Lombard, H. Golaconda Ramulu, E. Drula, P. M. Coutinho and B. Henrissat, The
464 carbohydrate-active enzymes database (CAZy) in 2013, *Nucleic Acids Res*, 2014, **42**,
465 D490-495.
- 466 17. B. H. Park, T. V. Karpinets, M. H. Syed, M. R. Leuze and E. C. Uberbacher, CAZymes
467 Analysis Toolkit (CAT): web service for searching and analyzing carbohydrate-active

- 468 enzymes in a newly sequenced organism using CAZy database, *Glycobiology*, 2010, **20**,
469 1574-1584.
- 470 18. I. Letunic, T. Yamada, M. Kanehisa and P. Bork, iPath: interactive exploration of
471 biochemical pathways and networks, *Trends Biochem Sci*, 2008, **33**, 101-103.
- 472 19. G. Bhinder, C. Garcia, F. Gräf, S. Crowley, E. Bosman, N. Ryz, J. Berkmann, R. Dyer, S.
473 Innis and B. Vallance, The Impact of Formula fortified with Milk Fat Globule Membrane
474 on the Neonatal Intestine, *The FASEB Journal*, 2016, **30**, 1b244-1b244.
- 475 20. T. Truong, M. Palmer, N. Bansal and B. Bhandari, in *Effect of Milk Fat Globule Size on*
476 *the Physical Functionality of Dairy Products*, Springer, 2016, pp. 5-9.
- 477 21. C. Garcia and S. Innis, Structure of the human milk fat globule, *Lipid Technology*, 2013,
478 **25**, 223-226.
- 479 22. F. Bäckhed, J. Roswall, Y. Peng, Q. Feng, H. Jia, P. Kovatcheva-Datchary, Y. Li, Y. Xia,
480 H. Xie and H. Zhong, Dynamics and stabilization of the human gut microbiome during
481 the first year of life, *Cell host & microbe*, 2015, **17**, 690-703.
- 482 23. J. E. Koenig, A. Spor, N. Scalfone, A. D. Fricker, J. Stombaugh, R. Knight, L. T.
483 Angenent and R. E. Ley, Succession of microbial consortia in the developing infant gut
484 microbiome, *Proceedings of the National Academy of Sciences*, 2011, **108**, 4578-4585.
- 485 24. R. Locke, Preventing obesity: the breast milk-leptin connection, *Acta Paediatrica*, 2002,
486 **91**, 891-894.
- 487 25. S. Gallier, K. Vocking, J. A. Post, B. Van De Heijning, D. Acton, E. M. Van Der Beek
488 and T. Van Baalen, A novel infant milk formula concept: Mimicking the human milk fat
489 globule structure, *Colloids and Surfaces B: Biointerfaces*, 2015, **136**, 329-339.

- 490 26. B. L. Cantarel, V. Lombard and B. Henrissat, Complex carbohydrate utilization by the
491 healthy human microbiome, *PLoS One*, 2012, **7**, e28742.
- 492 27. F. Fava, R. Gitau, B. A. Griffin, G. R. Gibson, K. M. Tuohy and J. A. Lovegrove, The
493 type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain
494 fatty acid excretion in a metabolic syndrome 'at-risk' population, *Int J Obes (Lond)*, 2013,
495 **37**, 216-223.
- 496 28. P. J. Turnbaugh, B. Henrissat and J. I. Gordon, Viewing the human microbiome through
497 three-dimensional glasses: integrating structural and functional studies to better define the
498 properties of myriad carbohydrate-active enzymes, *Acta Crystallogr Sect F Struct Biol*
499 *Cryst Commun*, 2010, **66**, 1261-1264.
- 500 29. F. Fava, R. Gitau, B. Griffin, G. Gibson, K. Tuohy and J. Lovegrove, The type and
501 quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty
502 acid excretion in a metabolic syndrome 'at-risk' population, *International Journal of*
503 *Obesity*, 2013, **37**, 216-223.
- 504 30. H. J. Flint, The impact of nutrition on the human microbiome, *Nutrition reviews*, 2012,
505 **70**, S10-S13.
- 506 31. E. G. Zoetendal, J. Raes, B. van den Bogert, M. Arumugam, C. C. Booiijink, F. J. Troost,
507 P. Bork, M. Wels, W. M. de Vos and M. Kleerebezem, The human small intestinal
508 microbiota is driven by rapid uptake and conversion of simple carbohydrates, *The ISME*
509 *journal*, 2012, **6**, 1415-1426.
- 510 32. A. R. Pacheco, D. Barile, M. A. Underwood and D. A. Mills, The impact of the milk
511 glycobiome on the neonate gut microbiota, *Annual review of animal biosciences*, 2015, **3**,
512 419.

- 513 33. T. Bhattacharya, T. S. Ghosh and S. S. Mande, Global Profiling of Carbohydrate Active
514 Enzymes in Human Gut Microbiome, *PLoS One*, 2015, **10**, e0142038.
- 515 34. A. El Kaoutari, F. Armougom, Q. Leroy, B. Vialettes, M. Million, D. Raoult and B.
516 Henrissat, Development and Validation of a Microarray for the Investigation of the
517 CAZymes Encoded by the Human Gut Microbiome, *PloS one*, 2013, **8**, e84033.
- 518 35. J. M. Brulc, D. A. Antonopoulos, M. E. Miller, M. K. Wilson, A. C. Yannarell, E. A.
519 Dinsdale, R. E. Edwards, E. D. Frank, J. B. Emerson, P. Wacklin, P. M. Coutinho, B.
520 Henrissat, K. E. Nelson and B. A. White, Gene-centric metagenomics of the fiber-
521 adherent bovine rumen microbiome reveals forage specific glycoside hydrolases, *Proc*
522 *Natl Acad Sci U S A*, 2009, **106**, 1948-1953.
- 523 36. A. El Kaoutari, F. Armougom, J. I. Gordon, D. Raoult and B. Henrissat, The abundance
524 and variety of carbohydrate-active enzymes in the human gut microbiota, *Nature Reviews*
525 *Microbiology*, 2013, **11**, 497-504.
- 526 37. S. Klaus, Adipose tissue as a regulator of energy balance, *Current drug targets*, 2004, **5**,
527 241-250.
- 528 38. A. Z. Fernandis and M. R. Wenk, Membrane lipids as signaling molecules, *Current*
529 *opinion in lipidology*, 2007, **18**, 121-128.
- 530 39. V. K. Babayan, Medium chain triglycerides and structured lipids, *Lipids*, 1987, **22**, 417-
531 420.
- 532 40. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis and J. I. Gordon,
533 An obesity-associated gut microbiome with increased capacity for energy harvest, *nature*,
534 2006, **444**, 1027-1131.

- 535 41. P. J. Turnbaugh, M. Hamady, T. Yatsunenko, B. L. Cantarel, A. Duncan, R. E. Ley, M.
536 L. Sogin, W. J. Jones, B. A. Roe and J. P. Affourtit, A core gut microbiome in obese and
537 lean twins, *nature*, 2009, **457**, 480-484.
- 538 42. P. J. Turnbaugh, V. K. Ridaura, J. J. Faith, F. E. Rey, R. Knight and J. I. Gordon, The
539 effect of diet on the human gut microbiome: a metagenomic analysis in humanized
540 gnotobiotic mice, *Science translational medicine*, 2009, **1**, 6ra14-16ra14.
- 541 43. C. Bourlieu and M. C. Michalski, Structure-function relationship of the milk fat globule,
542 *Current Opinion in Clinical Nutrition and Metabolic Care*, 2015, **18**, 118-127.
- 543 44. Q. Peng, X. Wang, M. Shang, J. Huang, G. Guan, Y. Li and B. Shi, Isolation of a novel
544 alkaline-stable lipase from a metagenomic library and its specific application for milkfat
545 flavor production, *Microbial cell factories*, 2014, **13**, 1.
- 546 45. P. Veiga, N. Pons, A. Agrawal, R. Oozeer, D. Guyonnet, R. Brazeilles, J.-M. Faurie, J. E.
547 van Hylckama Vlieg, L. A. Houghton and P. J. Whorwell, Changes of the human gut
548 microbiome induced by a fermented milk product, *Scientific reports*, 2014, **4**.
- 549 46. R. E. Ley, Obesity and the human microbiome, *Curr Opin Gastroenterol*, 2010, **26**, 5-11.
- 550 47. L. Aronsson, Y. Huang, P. Parini, M. Korach-André, J. Hakansson, J.-A. Gustafsson, S.
551 Pettersson, V. Arulampalam and J. Rafter, Decreased fat storage by *Lactobacillus*
552 *paracasei* is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4),
553 *PloS one*, 2010, **5**, e13087.
- 554 48. I. Bondia-Pons, T. Hyötyläinen and M. Orešič, in *Metabonomics and Gut Microbiota in*
555 *Nutrition and Disease*, Springer, 2015, pp. 235-260.

- 556 49. S. K. V. Gallier, Jan Andries Post, Bert Van De Heijning, Dennis Acton, Eline M. Van
557 Der Beek, Ton Van Baalen, A novel infant milk formula concept: Mimicking the human
558 milk fat globule structure, *Colloids and Surfaces B: Biointerfaces*, 2015, **136**, 329-339.
- 559 50. Z. L. Dai, G. Wu and W. Y. Zhu, Amino acid metabolism in intestinal bacteria: links
560 between gut ecology and host health, *Front Biosci (Landmark Ed)*, 2011, **16**, 1768-1786.
- 561 51. F. Blachier, F. Mariotti, J. F. Huneau and D. Tome, Effects of amino acid-derived
562 luminal metabolites on the colonic epithelium and physiopathological consequences,
563 *Amino Acids*, 2007, **33**, 547-562.
- 564 52. O. Ballard and A. L. Morrow, Human milk composition: nutrients and bioactive factors,
565 *Pediatric Clinics of North America*, 2013, **60**, 49-74.
- 566 53. G. Brisson, H. F. Payken, J. P. Sharpe and R. Jimenez-Flores, Characterization of
567 *Lactobacillus reuteri* Interaction with Milk Fat Globule Membrane Components in Dairy
568 Products, *Journal of Agricultural and Food Chemistry*, 2010, **58**, 5612-5619.
- 569 54. C. Iniguez, J. Sharpe, E. Acedo-Felix and R. Jimenez-Flores, Evaluation of adherence of
570 *Bifidobacterium* and *Lactobacillus* strains to cell membranes by blot analysis and optical
571 tweezers, *Journal of Animal Science*, 2006, **84**, 182-182.
- 572 55. C. Iniguez-Palomares, R. Jimenez-Flores, L. Vazquez-Moreno, G. Ramos-Clamont-
573 Montfort and E. Acedo-Felix, Protein-carbohydrate interactions between *Lactobacillus*
574 *salivarius* and pig mucins, *Journal of Animal Science*, 2011, **89**, 3125-3131.
- 575 56. P. D. Cani, J. Amar, M. A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A. M. Neyrinck, F.
576 Fava, K. M. Tuohy, C. Chabo, A. Waget, E. Delmee, B. Cousin, T. Sulpice, B.
577 Chamontin, J. Ferrieres, J. F. Tanti, G. R. Gibson, L. Casteilla, N. M. Delzenne, M. C.

- 578 Alessi and R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance,
579 *Diabetes*, 2007, **56**, 1761-1772.
- 580 57. N. Larsen, F. K. Vogensen, F. W. van den Berg, D. S. Nielsen, A. S. Andreasen, B. K.
581 Pedersen, W. A. Al-Soud, S. J. Sorensen, L. H. Hansen and M. Jakobsen, Gut microbiota
582 in human adults with type 2 diabetes differs from non-diabetic adults, *PLoS One*, 2010, **5**,
583 e9085.
- 584 58. A. Vrieze, E. Van Nood, F. Holleman, J. Salojarvi, R. S. Kootte, J. F. Bartelsman, G. M.
585 Dallinga-Thie, M. T. Ackermans, M. J. Serlie, R. Oozeer, M. Derrien, A. Druesne, J. E.
586 Van Hylckama Vlieg, V. W. Bloks, A. K. Groen, H. G. Heilig, E. G. Zoetendal, E. S.
587 Stroes, W. M. de Vos, J. B. Hoekstra and M. Nieuwdorp, Transfer of intestinal
588 microbiota from lean donors increases insulin sensitivity in individuals with metabolic
589 syndrome, *Gastroenterology*, 2012, **143**, 913-916 e917.
- 590 59. A. C. Gomes, A. A. Bueno, R. G. de Souza and J. F. Mota, Gut microbiota, probiotics
591 and diabetes, *Nutr J*, 2014, **13**, 60.
- 592 60. I. Moreno-Indias, F. Cardona, F. J. Tinahones and M. I. Queipo-Ortuño, Impact of the gut
593 microbiota on the development of obesity and type 2 diabetes mellitus, *Recent*
594 *Discoveries in Evolutionary and Genomic Microbiology*, 2015, 57.
- 595 61. A. D. Kostic, R. J. Xavier and D. Gevers, The microbiome in inflammatory bowel
596 disease: current status and the future ahead, *Gastroenterology*, 2014, **146**, 1489-1499.
- 597 62. J. Martin-de-Carpi, A. Rodriguez, E. Ramos, S. Jimenez, M. J. Martinez-Gomez, E.
598 Medina and H. y. N. P. Spirit-Ibd Working Group of Sociedad Espanola de
599 Gastroenterologia, Increasing incidence of pediatric inflammatory bowel disease in Spain
600 (1996-2009): the SPIRIT Registry, *Inflamm Bowel Dis*, 2013, **19**, 73-80.

- 601 63. A. Darfeuille-Michaud, J. Boudeau, P. Bulois, C. Neut, A. L. Glasser, N. Barnich, M. A.
602 Bringer, A. Swidsinski, L. Beaugerie and J. F. Colombel, High prevalence of adherent-
603 invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease,
604 *Gastroenterology*, 2004, **127**, 412-421.
- 605 64. T. Ohkusa, N. Sato, T. Ogihara, K. Morita, M. Ogawa and I. Okayasu, *Fusobacterium*
606 *varium* localized in the colonic mucosa of patients with ulcerative colitis stimulates
607 species-specific antibody, *J Gastroenterol Hepatol*, 2002, **17**, 849-853.
- 608 65. X. C. Morgan, T. L. Tickle, H. Sokol, D. Gevers, K. L. Devaney, D. V. Ward, J. A.
609 Reyes, S. A. Shah, N. LeLeiko, S. B. Snapper, A. Bousvaros, J. Korzenik, B. E. Sands, R.
610 J. Xavier and C. Huttenhower, Dysfunction of the intestinal microbiome in inflammatory
611 bowel disease and treatment, *Genome Biol*, 2012, **13**, R79.
- 612 66. A. R. Erickson, B. L. Cantarel, R. Lamendella, Y. Darzi, E. F. Mongodin, C. Pan, M.
613 Shah, J. Halfvarson, C. Tysk, B. Henrissat, J. Raes, N. C. Verberkmoes, C. M. Fraser, R.
614 L. Hettich and J. K. Jansson, Integrated metagenomics/metaproteomics reveals human
615 host-microbiota signatures of Crohn's disease, *PLoS One*, 2012, **7**, e49138.
- 616 67. A. Tursi, G. Brandimarte, G. M. Giorgetti, G. Forti, M. E. Modeo and A. Gigliobianco,
617 Low-dose balsalazide plus a high-potency probiotic preparation is more effective than
618 balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative
619 colitis, *Med Sci Monit*, 2004, **10**, PI126-131.

620

621 **FIGURE LEGENDS**

622 **Figure 1.** Frontal view of the ultracentrifuge tubes after sucrose density gradient separation from
623 buttermilk powder (BMP). Panel A shows the BMP without bacteria, the remaining tubes (1063-

624 S, 23272, SD2112 and T-1) represent different *Lactobacillus ruteri* strains. Panel B shows the
625 bottom of the tubes, with bacterial pellets that did not interact with the BMP.

626 **Figure 2.** Cell-surface proteins of seven lactic bacteria strains (NCFM, SlpA, SlpB, SlpX, MUB,
627 FpbA and CdpA) grown in 4 different media as acquired from PAGE results. Media included
628 MRS=laboratory media, P=milk permeate from 10K mw cut-off UF, M=same permeate but with
629 added 1% w/w MFGM fraction and UHT=Ultra High Temperature treated whole milk. Surface
630 proteins isolated from the lactic acid bacteria represent the different surface proteins, and the
631 numbers in the color coded legend represent their respective molecular weight (MW). Stacking
632 of the rectangles represent the bands detected for each strain under each treatment.

633 **Figure 3.** Confocal microscope images of the binding effects to fat globules of *L. casei* strain
634 SlpA in cream (Panel A), buttermilk (Panel B) and milk (Panel C). Confocal laser scanning
635 microscopy (CLSM) was used to visualize the binding of the different strains to the MFGM
636 structure in the reconstituted BMP. The BMP was reconstituted and labeled with the
637 phosphatidylethanolamine-lissamine rhodamine B (RH-PE) probe (Avanti, Alabaster, AL). Two-
638 mL of the RH-PE probe was first evaporated in a microcentrifuge tube for 5 min and then
639 suspended in 225 mL of PBS. Alternatively, cream (10% w/w in PBS, pH 7.2) isolated from raw
640 milk by centrifugation (3200g ´ 5 min) was similarly labeled with RH-PE. The dairy product (25
641 mL) was added and allowed to contact with the probe for 15 min at room temperature protected
642 from light. The bacteria suspension (A600 at 2.0 in PBS) was stained with acridine orange (AO)
643 hydrochloride (10mg/mL in water, Sigma, St-Louis, MO) at a ratio of 1:1000. The samples were
644 incubated for 5 min at room temperature protected from light before being washed twice with
645 PBS. Equal volume of the labeled bacteria and the dairy products were then mixed and allowed
646 to incubate for 15 min. The labeled samples were mixed 1:2 with agarose (0.5% w/v) before

647 being transferred to the confocal microscope slide. The samples were imaged with a CLSM
648 Fluoview FV1000 inverted microscope system (Olympus America Inc, Center Valley, PA) using
649 a Plan Apo N 60x 1.42NA immersion oil objective lens (Olympus). Laser excitation parameters
650 were set at 559 nm and 488 nm for the RH-PE and the AO probes respectively and the emission
651 spectra were recorded using a fluorescence detector (405/488/559). The images were analyzed
652 with the Fluoview FV1000 software (Olympus, Version 1.7.2.2.).

653 **Figure 4.** Flowchart of the potential applications of shotgun metagenomics to understand the
654 genetic changes resulting from the binding of *L. casei* strain SlpA to different milk products.
655 Flowchart also demonstrates the potential applications of targeted amplicon sequencing (TAS)
656 and shotgun metagenomics to understand how the consumption of milk products may potentially
657 affect microbial communities in the human gut.

658

659

Table 1. Binding rates and forces between different *Lactobacillus* strains and milk fat globules as determined using optical tweezers [44].

Bacteria	Binding rate (%)	Binding forces (pN)
<i>Lactobacillus reuteri</i> 1063-S	8	10-15
<i>Lactobacillus reuteri</i> 23272	11	10-15
<i>Lactobacillus reuteri</i> SD2112	33	15-180
<i>Lactobacillus reuteri</i> T-1	57	30->200




Figure 1. Frontal view of the ultracentrifuge tubes after sucrose density gradient separation from buttermilk powder (BMP). Panel A shows the BMP without bacteria, the remaining tubes (1063-S, 23272, SD2112 and T-1) represent different *Lactobacillus ruteri* strains. Panel B shows the bottom of the tubes, with bacterial pellets that did not interact with the BMP.

167x138mm (300 x 300 DPI)




Figure 2. Cell-surface proteins of seven lactic acid bacteria strains (NCFM, SlpA, SlpB, SlpX, MUB, FpbA and CdpA) grown in 4 different media as acquired from PAGE results. Media included MRS=laboratory media, P=milk permeate from 10K mw cut-off UF, M=same permeate but with added 1% w/w MFGM fraction and UHT=Ultra High Temperature treated whole milk. Surface proteins isolated from the lactic acid bacteria represent the different surface proteins, and the numbers in the color coded legend represent their respective molecular weight (MW). Stacking of the rectangles represent the bands detected for each strain under each treatment.

168x98mm (300 x 300 DPI)




Figure 3. Confocal microscope images of the binding effects to fat globules of *L. casei* strain SIpA in cream (Panel A), buttermilk (Panel B) and milk (Panel C).

293x70mm (300 x 300 DPI)




Figure 4. Flowchart of the potential applications of shotgun metagenomics to understand the genetic changes resulting from the binding of *L. casei* strain SIpA to different milk products. Flowchart also demonstrates the potential applications of targeted amplicon sequencing (TAS) and shotgun metagenomics to understand how the consumption of milk products may potentially affect microbial communities in the human gut.

246x313mm (300 x 300 DPI)